To boost our gains, we leverage our expert edge in the forecasting of biotech binary events outcomes. As important catalytic developments for clinical stage biotech companies, these events entail either an FDA approval and significant clinical data report. Whenever a drug either passes through a major clinical hurdle or gains FDA approval, their stock is positioned for a robust rally. Conversely, their stocks nearly always crash with a negative event result. Hence, having deep expertise is crucial for success in this niche.